Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer

Conclusions Among patients with NSCLC, BAP was associated with deteriorating PS during the first cycle of chemotherapy, grade  ≥ 3 diarrhea, febrile neutropenia, and stomatitis. Therefore, careful observation is needed for patients with NSCLC who receive Bev in any line of treatment, especially if they develop serious side effects that affect their PS or mucous membrane.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research